PENGARUH GEN Peroxisome proliferator-activated receptor γ (PPARγ) coactivator-1α (PGC-1α) TERHADAP PERKEMBANGAN PENYAKIT KARDIOVASKULAR
Abstract
ABSTRAK
Gen PGC-1α sebagai pengatur metabolisme sel, biogenesis mitokondria, mempengaruhi regulasi sel endotel dan sel otot polos yang berkaitan dengan perkembangan penyakit vaskular terutama penyakit aterosklerosis. PGC-1α dapat mengontrol beberapa aspek fungsi otot terkait dengan olahraga, karena PGC-1α dapat mengontrol paralisis otot, menekan respon inflamasi yang luas dan memediasi efek baik akibat olahraga. Peningkatan PGC-1α dapat mencegah dan mempengaruhi regresi lesi penyakit terutama aterosklerosis. Ekspresi PGC-1α yang rendah berhubungan dengan kejadian gagal jantung akibat stres dan kematian sel kardiomiosit. Disfungsi PGC-1α kemungkinan mendasari patologi penyebab berbagai penyakit degerenratif, termasuk kardiovaskular, penyakit degenerasi saraf, dan kanker.
ABSTRACT
Gene of PGC-1α functions as a regulator of cell metabolism, mitochondrial biogenesis, affects the regulation of endothelial cells and smooth muscle cells that are related to the development of vascular diseases, especially atherosclerosis. PGC-1α can control several aspects of muscle function related to exercise, as PGC-1α can control muscle paralysis, suppress extensive inflammatory responses and mediate exercise-induced good effects. Increased PGC-1α may prevent and influence regression of disease lesions especially atherosclerosis, whereas lack of PGC-1α levels are associated with the incidence of stress-induced heart failure and cardiomyocyte cell death. PGC-1α dysfunction likely underlies the causative pathology of various degenerative diseases, including cardiovascular, neurodegenerative diseases, and cancer.
Downloads
References
Kadlec AO, Chabowski DS, Ait-Aissa K, Hockenberry JC, Otterson MF, Durand MJ, et al. PGC-1α (Peroxisome Proliferator-Activated Receptor γ Coactivator 1-α) Overexpression in Coronary Artery Disease Recruits NO and Hydrogen Peroxide during Flow-Mediated Dilation and Protects Against Increased Intraluminal Pressure. Hypertension. 2017;70(1):166–73.
Pane JP, Simorangkir L, Saragih PISB. Faktor-Faktor Risiko Penyakit Kardivaskular Berbasis Masyarakat. J Penelit Perawat Prof. 2022;4(4):1183–92.
Setiadi AP, Halim SV. Penyakit Kardiovaskular. Graha Ilmu. 2018. 1–9 p.
Kadlec O, Barnes C, Durand MJ, Gutterman DD. Microvascular Adaptations to Exercise: Protective Effect of PGC-1 Alpha. Am J Hypertens. 2018;31(2):240–6.
Spiegelman CH and BM. The role of exercise and PGC1α in inflammation and chronic disease. NIH Public Acces. 2008;454(7203):463–9.
Kadlec AO, Chabowski DS, Ait-Aissa K, Gutterman DD. Role of PGC-1α in Vascular Regulation: Implications for Atherosclerosis. Arterioscler Thromb Vasc Biol. 2016;36(8):1467–74.
Cheng CF, Ku HC, Lin H. Pgc-1α as a pivotal factor in lipid and metabolic regulation. Int J Mol Sci. 2018;19(11):1–21.
Di W, Lv J, Jiang S, Lu C, Yang Z, Ma Z, et al. PGC-1: The energetic regulator in cardiac metabolism. Curr Issues Mol Biol. 2018;28:29–46.
Siasos G, Tsigkou V, Kosmopoulos M, Theodosiadis D, Simantiris S, Tagkou NM, et al. Mitochondria and cardiovascular diseases—from pathophysiology to treatment. Ann Transl Med. 2018;6(12):256–256.
Martínez-Redondo V, Pettersson AT, Ruas JL. The hitchhiker’s guide to PGC-1α isoform structure and biological functions. Diabetologia. 2015;58(9):1969–77.
Christian Riehle EDA. PGC-1 Proteins and Heart Failure. NIH Public Acces. 2012;22(4):98–105.
Chen L, Qin Y, Liu B, Gao M, Li A, Li X, et al. PGC-1α-Mediated Mitochondrial Quality Control: Molecular Mechanisms and Implications for Heart Failure. Front Cell Dev Biol. 2022;10(May):1–12.
Fabregat-Andrés Ó, Ridocci-Soriano F, Estornell-Erill J, Corbí-Pascual M, Valle-Muñoz A, Berenguer-Jofresa A, et al. Blood PGC-1α concentration predicts myocardial salvage and ventricular remodeling after st-segment elevation acute myocardial infarction. Rev Esp Cardiol. 2015;68(5):408–16.
Oka SI, Sabry AD, Cawley KM, Warren JS. Multiple Levels of PGC-1α Dysregulation in Heart Failure. Front Cardiovasc Med. 2020;7(January):1–17.
Teixeira RB, Barboza TE, de Araújo CC, Siqueira R, de Castro AL, Bonetto JHP, et al. Decreased PGC1-α levels and increased apoptotic protein signaling are associated with the maladaptive cardiac hypertrophy in hyperthyroidism. J Biosci. 2018;43(5):887–95.
Craige SM, Kröller-Schön S, Li C, Kant S, Cai S, Chen K, et al. PGC-1α dictates endothelial function through regulation of eNOS expression. Sci Rep. 2016;6:1–9.
Oehler D, Spychala A, Gödecke A, Lang A, Gerdes N, Ruas J, et al. Full-length transcriptomic analysis in murine and human heart reveals diversity of PGC-1α promoters and isoforms regulated distinctly in myocardial ischemia and obesity. BMC Biol [Internet]. 2022;20(1):169. Available from: https://doi.org/10.1186/s12915-022-01360-w
Jones AWE, Yao Z, Vicencio JM, Karkucinska-Wieckowska A, Szabadkai G. PGC-1 family coactivators and cell fate: Roles in cancer, neurodegeneration, cardiovascular disease and retrograde mitochondria-nucleus signalling. Mitochondrion [Internet]. 2012;12(1):86–99. Available from: http://dx.doi.org/10.1016/j.mito.2011.09.009
Institutet K. Structure and Function Relationships in the Pgc-1 Family of Transcriptional. 2018.
Svensson K, Handschin C. Modulation of PGC-1α activity as a treatment for metabolic and muscle-related diseases. Drug Discov Today. 2014;19(7):1024-1029. doi:10.1016/j.drudis.2014.02.013
Copyright (c) 2024 Medika Alkhairaat : Jurnal Penelitian Kedokteran dan Kesehatan
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with Medika Alkhairaat : Jurnal Penelitian Kedokteran dan Kesehatan agree to the following terms:
1. Authors retain copyright and grant Journal Medika Alkhairaat right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/) that allows others to remix, adapt, build upon the work non-commercially with an acknowledgement of the work’s authorship and initial publication in Journal Medika Alkhairaat.
2. Authors are permitted to copy and redistribute the journal’s published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in Journal Medika Alkhairaat.
